Oncology, Multinationals Dominate Japan 2017 Approvals
Executive Summary
It was another busy year for Japanese regulators, who approved 38 new drugs in the fiscal year up to the end of this March, roughly maintaining the pace of the the previous 12 months and bringing some important new therapies to patients. New products for oncology and biologics featured heavily, with foreign multinationals dominating the list.
You may also be interested in...
Scant Pipeline Competition For Roche’s Novel Flu Antiviral
With Priority Review given to Roche’s novel flu antiviral baloxavir marboxil for potential approval in the US, and Shionogi’s launch of the product under the brand name Xofluza, it looks set to lead the market for single-dose antivirals.
Herceptin, Enbrel Face First Biosimilar Rivals In Japan But Outlook Uncertain
The first biosimilar versions in Japan of two major biologic therapies, Herceptin and Enbrel, have been awarded reimbursement prices, clearing the way for launch, but commercial prospects remain uncertain.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.